Glycemic variability (GV), defined as an integral component of glucose homoeostasis, is emerging as an important metric to consider when assessing glycemic control in clinical practice. Although it remains yet no consensus, accumulating evidence has suggested that GV, representing either short-term (with-day and between-day variability) or long-term GV, was associated with an increased risk of diabetic macrovascular and microvascular complications, hypoglycemia, mortality rates and other adverse clinical outcomes. In this review, we summarize the adverse clinical outcomes of GV and discuss the beneficial measures, including continuous glucose monitoring, drugs, dietary interventions and exercise training, to improve it, aiming at better addressing the challenging aspect of blood glucose management.

No abstract

Aminoacyl-tRNA synthetases (ARSs) catalyze the ligation of amino acids to their cognate transfer RNAs (tRNAs), thus playing an important role in protein synthesis. In eukaryotic cells, these enzymes exist in free form or in the form of multi-tRNA synthetase complex (MSC). The latter contains nine cytoplasmic ARSs and three ARS-interacting multifunctional proteins (AIMPs). Normally, ARSs and AIMPs are regarded as housekeeping molecules without additional functions. However, a growing number of studies indicate that ARSs are involved in a variety of physiological and pathological processes, especially tumorigenesis. Here, we introduce the roles of ARSs and AIMPs in certain cancers, such as colon cancer, lung cancer, breast cancer, gastric cancer and pancreatic cancer. Furthermore, we particularly focus on their potential clinical applications in cancer, aiming at providing new insights into the pathogenesis and treatment of cancer.

ObjectiveThis study aimed to compare the prevalence of potentially inappropriate medications (PIMs) among hospitalized elderly patients using Beers and Chinese criteria and identify the correlation between PIMs and the risk of hospital readmission and death.MethodsThis study was conducted on geriatric patients aged ≥65 years at Beijing Fuxing Hospital between June 2015 and December 2017. The Beers criteria of 2015 and the Chinese criteria of 2017 were used to detect PIMs. Follow-ups were conducted for 12–36 months (or until patients’ death, if it came sooner). Cox proportional-hazards models were used to explore the correlations between PIM use and the risk of hospital readmission and death.ResultsOf 508 patients, 352 (69.3%) and 339 (66.7%) had at least one PIM identified using the Beers criteria and the Chinese criteria, respectively. Proton-pump inhibitors in the Beers criteria and clopidogrel in the Chinese criteria were the most leading PIMs. PIMs identified using the Beers criteria were a risk factor for the all-cause hospital readmission. After adjusting for age, gender, comorbidity, and so forth, PIM use was still an indicator of rehospitalization. PIM grouping defined using the Chinese criteria was not associated with hospital readmission. PIM grouping defined using either criteria was not associated with all-cause death.ConclusionThe study showed a high prevalence of PIM use in China. PIMs defined using the Beers criteria increased the risk of hospital readmission. Clinicians should pay more attention to PIMs, carry out routine PIM assessment, and reduce adverse health outcomes in elderly patients.

No abstract